Abstract
Matthew H. Thomas, Ted M. Ross
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Unresolved referenced work
Kept as external metadata until matched
10.15585/mmwr.rr7305a1
10.15585/mmwr.rr7305a1
Unresolved referenced work
Kept as external metadata until matched
10.1128/jvi.00797-19
10.1128/jvi.00797-19
10.3390/vaccines6020028
10.3390/vaccines6020028
10.1007/s40265-024-02083-8
10.1007/s40265-024-02083-8
10.3390/vaccines9020075
10.3390/vaccines9020075
10.3389/fimmu.2019.01677
10.3389/fimmu.2019.01677
Haemagglutination-inhibiting antibody to influenza virus
2003
10.1186/1471-2288-10-18
10.1186/1471-2288-10-18
10.1038/s41586-021-04356-8
10.1038/s41586-021-04356-8
10.3389/fimmu.2024.1499754
10.3389/fimmu.2024.1499754
10.3389/fimmu.2022.878943
10.3389/fimmu.2022.878943
10.1093/cid/ciab1016
10.1093/cid/ciab1016
10.1016/j.vaccine.2007.07.027
10.1016/j.vaccine.2007.07.027
10.1089/vim.2017.0129
10.1089/vim.2017.0129
10.1016/j.vaccine.2011.01.100
10.1016/j.vaccine.2011.01.100
Unresolved referenced work
2021
10.3390/vaccines9070793
10.3390/vaccines9070793
10.1128/jvi.01652-21
10.1128/jvi.01652-21
10.1002/rmv.2243
10.1002/rmv.2243
10.1038/s41392-023-01557-7
10.1038/s41392-023-01557-7
10.1016/j.vaccine.2019.02.002
10.1016/j.vaccine.2019.02.002
10.1038/s41467-025-64686-3
10.1038/s41467-025-64686-3
10.1093/jimmun/vkaf092
10.1093/jimmun/vkaf092
10.3390/vaccines8030462
10.3390/vaccines8030462
10.3390/vaccines14010103
10.3390/vaccines14010103
10.1016/j.vaccine.2019.08.071
10.1016/j.vaccine.2019.08.071
10.1016/j.vaccine.2026.128421
10.1016/j.vaccine.2026.128421
Unresolved referenced work
Kept as external metadata until matched
10.1007/978-1-0716-3690-9_3
10.1007/978-1-0716-3690-9_3
10.1371/journal.pcbi.1007294
10.1371/journal.pcbi.1007294
10.1038/s41541-022-00492-y
10.1038/s41541-022-00492-y
10.1038/s41541-018-0093-1
10.1038/s41541-018-0093-1
10.1038/s41598-020-79590-7
10.1038/s41598-020-79590-7
10.1128/jvi.01581-17
10.1128/jvi.01581-17
10.1016/j.str.2024.05.001
10.1016/j.str.2024.05.001
10.1038/s42003-023-04793-3
10.1038/s42003-023-04793-3
10.3390/pathogens10111352
10.3390/pathogens10111352
10.1016/j.vaccine.2023.12.084
10.1016/j.vaccine.2023.12.084 · doi-reference
10.1038/s41598-022-15238-y
10.1038/s41598-022-15238-y · doi-reference
10.4049/jimmunol.1301424
10.4049/jimmunol.1301424 · doi-reference
10.3389/fimmu.2021.729189
10.3389/fimmu.2021.729189 · doi-reference
10.1128/jvi.01526-20
10.1128/jvi.01526-20 · doi-reference
10.1126/science.aag1322
10.1126/science.aag1322 · doi-reference
10.1146/annurev-virology-010320-044746
10.1146/annurev-virology-010320-044746 · doi-reference
10.1016/j.vaccine.2019.08.077
10.1016/j.vaccine.2019.08.077 · doi-reference